Abstract：
The aim of this study was to analyze the prognostic factors related to the recurrence rate and overall survival of patients with undifferentiated uterine sarcoma.
An international multicenter study involving 43 international centers, the SARCUT study, collected 966 uterine sarcoma cases; among them 39 cases corresponded to undifferentiated uterine sarcoma and where included in the present subanalysis. The risk factors related to the oncological outcomes where analyzed.
The median age of the patients was 63 (range 14-85) years. Seventeen (43.5%) patients presented FIGO stage I. The 5-year overall survival (OS) was 15.3% and 12-months disease-free survival (DFS) 41%. FIGO stage I was significantly associated with a better prognosis. In addition, patients who received adjuvant radiotherapy showed significant longer disease-free survival compared to those without adjuvant radiotherapy (20.5 vs. 4.0 months, respectively; p = 0.04) and longer overall survival (34.7 vs. 18.2 months, respectively; p = 0.05). Chemotherapy administration was associated with shorter DFS (HR 4.41, 95% CI 1.35-14.43, p = 0.014). Persistent disease after primary treatment (HR = 6.86, 95% CI 1.51-31.09, p = 0.012) and FIGO stage IV (HR 4.12, 95%CI 1.37-12.44, p = 0.011) showed significant worse prognosis for OS.
FIGO stage seems to be the most important prognostic factor in patients with undifferentiated uterine sarcoma. Adjuvant radiotherapy seems to be significantly associated also to a better disease-free and overall survival. On the contrary, the role of chemotherapy administration remains unclear since was associated to a shorted DFS.
An international multicenter study involving 43 international centers, the SARCUT study, collected 966 uterine sarcoma cases; among them 39 cases corresponded to undifferentiated uterine sarcoma and where included in the present subanalysis. The risk factors related to the oncological outcomes where analyzed.
The median age of the patients was 63 (range 14-85) years. Seventeen (43.5%) patients presented FIGO stage I. The 5-year overall survival (OS) was 15.3% and 12-months disease-free survival (DFS) 41%. FIGO stage I was significantly associated with a better prognosis. In addition, patients who received adjuvant radiotherapy showed significant longer disease-free survival compared to those without adjuvant radiotherapy (20.5 vs. 4.0 months, respectively; p = 0.04) and longer overall survival (34.7 vs. 18.2 months, respectively; p = 0.05). Chemotherapy administration was associated with shorter DFS (HR 4.41, 95% CI 1.35-14.43, p = 0.014). Persistent disease after primary treatment (HR = 6.86, 95% CI 1.51-31.09, p = 0.012) and FIGO stage IV (HR 4.12, 95%CI 1.37-12.44, p = 0.011) showed significant worse prognosis for OS.
FIGO stage seems to be the most important prognostic factor in patients with undifferentiated uterine sarcoma. Adjuvant radiotherapy seems to be significantly associated also to a better disease-free and overall survival. On the contrary, the role of chemotherapy administration remains unclear since was associated to a shorted DFS.
摘要：
目的：本研究的目的是分析与未分化子宫肉瘤患者的复发率和总生存期相关的预后因素。
方法：一项涉及43个国际中心的国际多中心研究，SARCUT的研究,收集了966例子宫肉瘤；其中39例对应于未分化子宫肉瘤，并包括在本亚分析中。与肿瘤学结果相关的危险因素分析。
结果：患者的中位年龄为63岁（范围14-85岁）。17例（43.5%）患者出现FIGO阶段I，5年总生存率（OS）为15.3%，12个月无病生存率（DFS）为41%。FIGO阶段I与更好的预后显着相关。此外,与未接受辅助放疗的患者相比，接受辅助放疗的患者无病生存期显著延长（20.5vs.4.0个月,分别为；p=0.04）和更长的总生存期（34.7vs.18.2个月，分别为；p=0.05)。化疗与较短的DFS相关(HR4.41,95%CI1.35-14.43,p=0.014)。主要治疗后的持续性疾病（HR=6.86，95％CI1.51-31.09，p=0.012）和FIGOIV期（HR4.12，95CI1.37-12.44，p=0.011）显示OS预后明显较差。
结论：FIGO分期似乎是未分化子宫肉瘤患者最重要的预后因素。辅助放疗似乎也与更好的无病生存率和总体生存率显着相关。相反,化疗的作用尚不清楚,因为化疗与DFS缩短相关.
方法：一项涉及43个国际中心的国际多中心研究，SARCUT的研究,收集了966例子宫肉瘤；其中39例对应于未分化子宫肉瘤，并包括在本亚分析中。与肿瘤学结果相关的危险因素分析。
结果：患者的中位年龄为63岁（范围14-85岁）。17例（43.5%）患者出现FIGO阶段I，5年总生存率（OS）为15.3%，12个月无病生存率（DFS）为41%。FIGO阶段I与更好的预后显着相关。此外,与未接受辅助放疗的患者相比，接受辅助放疗的患者无病生存期显著延长（20.5vs.4.0个月,分别为；p=0.04）和更长的总生存期（34.7vs.18.2个月，分别为；p=0.05)。化疗与较短的DFS相关(HR4.41,95%CI1.35-14.43,p=0.014)。主要治疗后的持续性疾病（HR=6.86，95％CI1.51-31.09，p=0.012）和FIGOIV期（HR4.12，95CI1.37-12.44，p=0.011）显示OS预后明显较差。
结论：FIGO分期似乎是未分化子宫肉瘤患者最重要的预后因素。辅助放疗似乎也与更好的无病生存率和总体生存率显着相关。相反,化疗的作用尚不清楚,因为化疗与DFS缩短相关.
